Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDQuarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 2 | -$1.54 | -$0.88 | -$1.26 |
Q2 2024 | 2 | -$1.58 | -$0.91 | -$1.29 |
Q3 2024 | 2 | -$1.37 | -$0.79 | -$1.12 |
Q4 2024 | 6 | -$1.20 | -$1.02 | -$1.13 |
Q1 2025 | 2 | -$1.46 | -$0.84 | -$1.20 |
Q2 2025 | 1 | $0.86 | $1.51 | $1.23 |
Q3 2025 | 1 | -$1.28 | -$0.73 | -$1.05 |
Q4 2025 | 1 | -$0.61 | -$0.35 | -$0.50 |
REGENXBIO Inc. last posted its earnings results on Wednesday, November 6th, 2024. The company reported $-1.17 earnings per share for the quarter, missing analysts' consensus estimates of $-1.16 by $0.01. The company had revenue of 24.20 M for the quarter and had revenue of 90.24 M for the year. REGENXBIO Inc. has generated $-6 earnings per share over the last year ($-6.02 diluted earnings per share) and currently has a price-to-earnings ratio of -1.58. REGENXBIO Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based on prior year's report dates.
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
11/06/2024 | Q3 2024 | -$1.16 | -$1.17 | -0.01 | $23.63 M | $24.20 M |
08/01/2024 | Q2 2024 | -$1.29 | -$1.05 | 0.24 | $22.97 M | $22.30 M |
05/08/2024 | Q1 2024 | -$1.28 | -$1.38 | -0.1 | $15.62 M | |
02/27/2024 | Q4 2023 | -$1.27 | -$1.43 | -0.16 | $22.21 M | |
11/08/2023 | Q3 2023 | -$1.44 | -$1.41 | 0.03 | $26.14 M | $28.91 M |
08/02/2023 | Q2 2023 | -$1.26 | -$1.66 | -0.4 | $34.50 M | $19.98 M |
05/03/2023 | Q1 2023 | -$1.52 | -$1.61 | -0.09 | $19.14 M | |
02/28/2023 | Q4 2022 | -$1.48 | -$1.38 | 0.1 | $31.35 M | |
11/03/2022 | Q3 2022 | -$1.55 | -$1.85 | -0.3 | $30.81 M | $26.51 M |
08/03/2022 | Q2 2022 | -$1.44 | -$1.58 | -0.14 | $28.31 M | $32.65 M |
05/04/2022 | Q1 2022 | -$1.29 | -$1.79 | -0.5 | $22.22 M | |
03/01/2022 | Q4 2021 | $4.71 | $6.87 | 2.16 | $398.66 M | |
11/02/2021 | Q3 2021 | -$0.87 | -$1.37 | -0.5 | $33.17 M | $30.77 M |
08/09/2021 | Q2 2021 | -$1.08 | -$1.36 | -0.28 | $21.17 M | $22.04 M |
05/05/2021 | Q1 2021 | -$1.13 | -$1.20 | -0.07 | $18.88 M | |
03/01/2021 | Q4 2020 | $1.11 | -$1.24 | -2.35 | $21.45 M | |
11/04/2020 | Q3 2020 | -$0.89 | $0.24 | 1.13 | $21.45 M | $98.91 M |
08/06/2020 | Q2 2020 | -$0.89 | -$0.91 | -0.02 | $20.46 M | $16.57 M |
05/07/2020 | Q1 2020 | -$0.87 | -$1.08 | -0.21 | $17.64 M | |
02/26/2020 | Q4 2019 | -$0.40 | -$0.72 | -0.32 | $11.77 M |
REGENXBIO Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates.
The conference call for REGENXBIO Inc.'s latest earnings report can be listened to online.
The conference call transcript for REGENXBIO Inc.'s latest earnings report can be read online.
REGENXBIO Inc. (:RGNX) has a recorded annual revenue of $90.24 M.
REGENXBIO Inc. (:RGNX) has a recorded net income of $90.24 M. REGENXBIO Inc. has generated $-6.02 earnings per share over the last four quarters.
REGENXBIO Inc. (:RGNX) has a price-to-earnings ratio of -1.58 and price/earnings-to-growth ratio is -0.35.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED